At a glance
- Originator Japan Tobacco
- Developer Japan Tobacco; Mitsubishi Pharma Corporation
- Class Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Prolyl endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dementia
Most Recent Events
- 04 Sep 1997 Discontinued-Preclinical for Dementia in Japan (Unknown route)
- 21 Jan 1997 Preclinical development for Dementia in Japan (Unknown route)